Cerebrolysin Research

Cerebrolysin research is unusual for two reasons. The compound is not a single molecule, and much of its large and contested human evidence base comes from trials run or supported by a single manufacturer. This article summarizes the published record, nulls and negatives included.

What Cerebrolysin is, and why it has no structure

Cerebrolysin is a peptide preparation made from purified porcine brain protein by standardized enzymatic breakdown, yielding a mixture of low-molecular-weight peptides and free amino acids. Cochrane's own standing description, carried unchanged across successive versions of its stroke review, calls it a mixture of low-molecular-weight peptides and amino acids derived from porcine brain ^[1].

Identity is defined by source material and manufacturing process rather than by chemistry. PubChem holds no compound record for Cerebrolysin, and returns no CID for its name or for CAS 12656-61-0. Identity lives at substance level instead, under FDA unique ingredient identifier 37KZM6S21G, and the FDA substance registry classifies it as structurally diverse material sourced from mammalian brain.

No molecular formula, molecular weight, SMILES string, InChI or amino acid sequence exists for this preparation, so any such figure printed for it has been invented. The FDA's own generic name for it is "peptide fraction derived from porcine brain protein".

Cortexin is a cattle brain preparation and Actovegin is a calf blood hemodialysate, so neither is Cerebrolysin, and neither one's evidence transfers. Composition is process-defined, so lot consistency is a fair question to ask. A literature search did not locate an independent published analysis of batch-to-batch composition, though the manufacturer asserts standardization. Neither consistency nor variability is established in the public record.

Regulatory status: authorized in some countries, not by the FDA

Cerebrolysin is a genuinely authorized prescription medicine, holding a national marketing authorization in Austria under EVER Neuro Pharma GmbH as a solution for injection given under medical supervision. Its Austrian indications cover supportive treatment of cerebrovascular disorders, including dementia, post-stroke deficits and craniocerebral trauma, and it is registered in various Eastern European, post-Soviet and Asian markets. Specific country counts circulate widely, but none could be verified from primary registers.

It is not approved by the FDA, with no match returned across the openFDA label, NDC and Drugs@FDA endpoints, including a query run by UNII. It is also not centrally authorized in the European Union, being absent from the European Commission's Union Register. A national approval elsewhere is neither an FDA approval nor an EMA central authorization.

Two records look like FDA approvals and are not. The FDA granted an orphan drug designation in April 2016 for frontotemporal dementia, and an orphan designation is a development incentive, never an approval. That designation's status now reads "Designated/Designation Withdrawn or Revoked", and its orphan approval status reads "Not FDA Approved for Orphan Indication". Separately, the FDA substance registry entry reports "status: approved", meaning the registry record itself has been validated. It is not a drug approval.

Mechanism claims rest largely on a compromised animal literature

The standard mechanistic account describes neurotrophic and neuroprotective activity resembling endogenous growth factors, resting largely on transgenic mouse work covering tau pathology, amyloid, neurogenesis and mitochondrial structure. Key studies in that body of animal research have since been retracted.

Ten PubMed-indexed papers involving Cerebrolysin carry the publication type "Retracted Publication", and four are the transgenic mouse studies most often cited for mechanism ^{[18][19][20][21]}. All four share a senior investigator, and several list employees of the manufacturer under its current and former names. A further animal paper carries an editorial expression of concern.

The retractions hit the preclinical literature rather than the clinical trials, and none of the human trials below appears in that retracted set. That distinction does not help the compound. The mechanism narrative is less well supported than its citation count suggests.

Cerebrolysin research in acute ischemic stroke

CASTA was the largest randomized trial ever run on Cerebrolysin, a double-blind, placebo-controlled study in 1,070 human patients with acute ischemic hemispheric stroke ^[4]. Its confirmatory primary endpoint showed no significant difference between the treatment groups. A favorable trend in severely affected patients came from a post hoc subgroup analysis, and the authors wrote that it should be confirmed by a further trial.

The current Cochrane review covers seven randomized trials and 1,773 human participants ^[1]. The 2023 update added a trial of Cortexin contributing 272 participants, so the all-cause death result belongs to the mixed set of Cerebrolysin or Cortexin: RR 0.96 (95% CI 0.65 to 1.41), moderate certainty. No included study reported poor functional outcome, early death, quality of life, or time to restoration of capacity for work. None of the trials Cochrane included measured the outcomes that would settle clinical usefulness. Cochrane judged two of the seven included studies at high risk of other bias and five at unclear risk. Incomplete outcome data was rated high risk in four of the seven, and selective outcome reporting was unclear across all of them. The 2020 version of the same review reached the same conclusion on a smaller dataset, with all-cause death RR 0.90 (95% CI 0.61 to 1.32) ^[2].

CARS was a randomized, double-blind, placebo-controlled trial of motor recovery in human patients after stroke, positive on its primary endpoint ^[5]. Its authors describe it as exploratory, with a relatively small sample. They called for confirmation in a large-scale randomized clinical trial.

C-REGS2 is positive on its primary and all secondary endpoints across 1,769 analyzed human patients ^[9], but its design limits what it can establish. It is an open-label, non-randomized, sponsor-run observational study, and its predecessor was terminated because matched comparison groups could not be assembled. It does not outweigh a randomized double-blind trial of comparable size that returned a neutral result. A separate sponsor-run phase 2 stroke trial of upper limb recovery was terminated for strategic and pandemic reasons, with four patients enrolled.

A European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline recommends Cerebrolysin for early neurorehabilitation after acute ischemic stroke ^[13]. Its literature search closed in June 2018, so it predates the 2020 and 2023 Cochrane updates. Its author list also includes several central figures from the manufacturer's clinical network.

Dementia and traumatic brain injury

Cochrane's vascular dementia review pools six randomized trials and 597 human participants, with cognition and global function both favoring Cerebrolysin ^[3]. Every pooled outcome was graded very low quality evidence. The authors state that the data are not definitive and that the included papers had high risk of bias. Any benefits, they add, may be too small to be clinically meaningful, and the supporting evidence base is weak. No new eligible trial has appeared since 2013.

In Alzheimer's disease, a sponsor-affiliated meta-analysis of six randomized human trials reported a significant cognitive effect at four weeks ^[10]. The same analysis found no significant cognitive effect at six months. An earlier independent meta-analysis reached significance only on clinical global impression, its authors writing that more convincing evidence was needed for cognition and daily living ^[11]. No Cochrane review of Cerebrolysin in Alzheimer's disease exists, and a 2002 Cochrane protocol was never converted into one. A sponsor-run phase 4 trial comparing Cerebrolysin against donepezil in mild to moderate dementia of the Alzheimer's type was withdrawn with zero participants enrolled. That head-to-head comparison against the standard-of-care drug was never run.

There is likewise no Cochrane review of Cerebrolysin in traumatic brain injury. CAPTAIN I, a randomized, double-blind, placebo-controlled trial, missed its primary endpoint in the intention-to-treat population, with significance appearing only in the per-protocol analysis ^[6]. It was terminated early for poor recruitment, reaching 46 patients, and its authors called for confirmation by a larger randomized trial. A sponsor-side prospective meta-analysis pooling it with a sibling trial reported a small-to-medium effect across 185 patients ^[7]. The confirmatory randomized trials that the CARS and CAPTAIN I authors called for have not been published. The development program moved to open-label observational designs instead ^[9].

The largest body of human TBI data is an independent systematic review and meta-analysis of ten clinical studies and 8,749 patients ^[8]. Those studies were both retrospective and prospective, and the pool is dominated by retrospective work, so it is lower-grade evidence than the randomized trials despite its size. Glasgow Coma Scale and Glasgow Outcome Scale scores changed significantly. Mortality of any cause and length of hospital stay were not affected in those patients.

Safety signals

Safety reads differently depending on which pooled analysis is taken. Cochrane reported little to no difference in the total number of people with serious adverse events, RR 1.16 (95% CI 0.81 to 1.66), moderate certainty ^[1]. Within that total, non-fatal serious adverse events were increased: RR 2.39 (95% CI 1.10 to 5.23), three trials, 1,335 human participants, moderate certainty. The increase was more pronounced in the two trials that used the more intensive exposure regimen: RR 2.87 (95% CI 1.24 to 6.69), 1,189 human participants. Those serious adverse event figures are Cerebrolysin-only, not the mixed set.

A larger, more recent pooled analysis of 14 randomized trials and 2,884 human patients found no significant difference in serious adverse events, RR 1.08 (95% CI 0.84 to 1.40), and none in mortality, RR 0.86 (0.68 to 1.09) ^[15]. Functional independence showed only a non-significant trend, RR 1.31 (0.90 to 1.91). That analysis appeared in a low-tier venue, and its one significant result was a stroke scale score rather than a hard outcome. It also omits the fatal and non-fatal split that produced Cochrane's signal.

A further independent systematic review, run by a university group rather than the manufacturer's network, found no difference in serious adverse events for Cerebrolysin specifically. The figure was RR 0.96 (95% CI 0.78 to 1.18), six trials, 1,014 human participants ^[14]. Its risk of bias across included studies was moderate to high, and its certainty of evidence low to very low.

A case report documents laboratory-confirmed, life-threatening anaphylaxis in one human patient after intravenous Cerebrolysin ^[16]. This is a foreign-species, protein-derived biological given by infusion, so hypersensitivity is a mechanistically coherent risk rather than an incidental observation.

Who produced the evidence

The strongest positive claims about Cerebrolysin come mainly from one manufacturer's clinical network, and that pattern is itself a finding. Cochrane records that the manufacturer supported three of the multicenter stroke studies, in some cases by supplying randomization codes and statisticians as well as funding ^[1]. Its 2020 version recorded four such studies ^[2], and its vascular dementia review records that every study with disclosed funding was industry-supported ^[3].

The same names recur across the positive literature. The statistician who designed the bespoke multivariate endpoints used throughout the program is first author of the CAPTAIN meta-analysis and a co-author of the Alzheimer's meta-analysis. He is affiliated to an external biometry contractor rather than to the manufacturer. The C-REGS2 conflict of interest statement records that he and two co-authors received honoraria from EVER Neuro Pharma ^[9].

Deflationary results come from both independent groups and the sponsor's own output. The independent set includes the successive Cochrane reviews, the Jarosz TBI meta-analysis, the Masserini vascular cognitive impairment synthesis and the Wei 2007 Alzheimer's meta-analysis. On the sponsor's side, CASTA missed its primary endpoint, CAPTAIN I failed its intention-to-treat analysis, and the Alzheimer's meta-analysis returned a six-month null. A 2025 synthesis of 173 vascular cognitive impairment trials and 22,347 human participants placed Cerebrolysin's cognitive effect in the small-to-moderate bracket, alongside physical exercise and cognitive rehabilitation ^[12]. An independent 2021 review pooling animal-derived nootropics as a class found the supporting evidence weak, and the effects probably smaller than would be clinically relevant ^[14]. Its Cerebrolysin-specific figures were a small cognitive effect, SMD -0.16 (95% CI -0.30 to -0.03), across eight trials and 793 human participants. Global function favored Cerebrolysin, OR 2.64 (95% CI 1.17 to 5.98), across four trials and 479 human participants. In the vascular cognitive impairment subgroup the cognitive effect was SMD -0.22 (95% CI -0.42 to -0.03). A frequently cited umbrella review lists cerebrolysin among beneficial Alzheimer's options, but it pools the meta-analyses already described and adds no new patient data ^[17].

Conclusion

Cerebrolysin has a larger human evidence base than most research peptides, and a weaker one than its usage implies. The authors of both flagship trials, CARS and CAPTAIN I, called for confirmatory randomized trials, and neither has been published. The negative finding in acute ischemic stroke has been stable across successive Cochrane updates. Identity here is defined by process, so material obtained outside the authorized supply chain carries no assurance of matching what was studied.

Frequently Asked Questions

Does Cerebrolysin have a molecular formula or an amino acid sequence? No. It is a preparation defined by source material and manufacturing process rather than by a single structure, and PubChem holds no compound record for it. Any molecular formula, molecular weight or sequence printed for this preparation has been invented.

Is Cerebrolysin FDA approved? It is not approved by the FDA and not centrally authorized in the European Union, though it does hold a national marketing authorization in Austria. Its FDA orphan drug designation for frontotemporal dementia was withdrawn or revoked, and an orphan designation is never an approval. The registry entry reading "status: approved" refers to validation of that record, not to drug approval.

Have the CARS and CAPTAIN I results been independently confirmed? No confirmatory randomized trial has been published for either. Both sets of authors called for larger randomized trials ^[5][6], and the development program moved to open-label observational designs instead ^[9]. CARS was positive on its primary endpoint, while CAPTAIN I missed its primary endpoint in the intention-to-treat population.

Do Cochrane's stroke figures apply to Cerebrolysin alone? Not all of them. The 2023 Cochrane update pooled a trial of Cortexin, a cattle brain preparation, so the all-cause death result applies to the mixed set of Cerebrolysin or Cortexin ^[1]. The serious adverse event figures in that review, including the increase in non-fatal serious adverse events, are Cerebrolysin-only.

References

1. 1

   Ziganshina LE, Abakumova T, Nurkhametova D, Ivanchenko K. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2023;10(10):CD007026. PMID 37818733.
2. 2

   Ziganshina LE, et al. Cerebrolysin for acute ischaemic stroke. Cochrane Database Syst Rev. 2020;7:CD007026. PMID 32662068.
3. 3

   Cui S, Chen N, Yang M, et al. Cerebrolysin for vascular dementia. Cochrane Database Syst Rev. 2019;11:CD008900. PMID 31710397.
4. 4

   Heiss WD, et al. Cerebrolysin in patients with acute ischemic stroke in Asia: results of a double-blind, placebo-controlled randomized trial. Stroke. 2012;43(3):630-636. PMID 22282884.
5. 5

   Muresanu DF, et al. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial. Stroke. 2016;47(1):151-159. PMID 26564102.
6. 6

   Poon W, et al. Safety and efficacy of Cerebrolysin in acute brain injury and neurorecovery: CAPTAIN I, a randomized, placebo-controlled trial. Neurol Sci. 2020;41(2):281-293. PMID 31494820. (erratum PMID 31909448.)
7. 7

   Vester JC, et al. Cerebrolysin after moderate to severe traumatic brain injury: prospective meta-analysis of the CAPTAIN trial series. Neurol Sci. 2021;42(11):4531-4541. PMID 33620612.
8. 8

   Jarosz K, et al. Cerebrolysin in patients with TBI: systematic review and meta-analysis. Brain Sci. 2023;13(3):507. PMID 36979317.
9. 9

   Vosko MR, et al. C-REGS2: a multinational, high-quality comparative effectiveness study of Cerebrolysin in moderate acute ischaemic stroke. Int J Stroke. 2025. PMID 40851188.
10. 10

    Gauthier S, Proaño JV, Jia J, Froelich L, Vester JC, Doppler E. Cerebrolysin in mild-to-moderate Alzheimer's disease: a meta-analysis of randomized controlled clinical trials. Dement Geriatr Cogn Disord. 2015;39(5-6):332-347. PMID 25832905.
11. 11

    Wei ZH, et al. Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease. J Neural Transm (Vienna). 2007;114(5):629-634. PMID 17318304.
12. 12

    Masserini F, et al. Therapeutic strategies in vascular cognitive impairment: a systematic review and meta-analysis. Alzheimers Dement. 2025;21(11). PMID 41198594.
13. 13

    Beghi E, Binder H, Birle C, et al. European Academy of Neurology and European Federation of Neurorehabilitation Societies guideline on pharmacological support in early motor rehabilitation after acute ischaemic stroke. Eur J Neurol. 2021;28(9):2831-2845. PMID 34152062.
14. 14

    Alsulaimani RA, Quinn TJ. The efficacy and safety of animal-derived nootropics in cognitive disorders: systematic review and meta-analysis. Cereb Circ Cogn Behav. 2021;2:100012. PMID 36324709. (erratum: Cereb Circ Cogn Behav. 2022;3:100038)
15. 15

    Patel PN, Mangal D, Patel K. Safety and efficacy of Cerebrolysin for neurorecovery after acute ischemic stroke: a systematic review and meta-analysis of 14 randomized controlled trials. Cureus. 2025;17(8):e91054. PMID 41018475.
16. 16

    Trimmel H, et al. Life-threatening anaphylaxis due to Cerebrolysin. Case Rep Neurol Med. 2024. PMID 39055722.
17. 17

    Fan F, et al. The efficacy and safety of Alzheimer's disease therapies: an updated umbrella review. J Alzheimers Dis. 2022;85(3):1195-1204. PMID 34924395.
18. 18

    Rockenstein E, et al. Neuroprotective effects of Cerebrolysin in triple repeat Tau transgenic model of Pick's disease and fronto-temporal tauopathies. BMC Neurosci. 2015;16:85. PMID 26611895. (RETRACTED)
19. 19

    Rockenstein E, et al. Cerebrolysin efficacy in a transgenic model of tauopathy: role in regulation of mitochondrial structure. BMC Neurosci. 2014;15:90. PMID 25047000. (RETRACTED)
20. 20

    Rockenstein E, et al. Regional comparison of the neurogenic effects of CNTF-derived peptides and cerebrolysin in AbetaPP transgenic mice. J Alzheimers Dis. 2011;27(4):743-752. PMID 21860085. (RETRACTED)
21. 21

    Doppler E, et al. Neurotrophic effects of Cerebrolysin in the Mecp2(308/Y) transgenic model of Rett syndrome. Acta Neuropathol. 2008;116(4):425-437. PMID 18600331. (RETRACTED)